11/17
04:41 pm
cadl
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 [Yahoo! Finance]
Low
Report
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 [Yahoo! Finance]
11/17
04:05 pm
cadl
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
Low
Report
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
11/15
01:42 am
cadl
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str
Low
Report
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str
11/14
03:09 pm
cadl
Candel Therapeutics (NASDAQ:CADL) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $24.00. They now have a "buy" rating on the stock.
11/13
12:28 pm
cadl
Candel Therapeutics GAAP EPS of -$0.21 misses by $0.03 [Seeking Alpha]
Medium
Report
Candel Therapeutics GAAP EPS of -$0.21 misses by $0.03 [Seeking Alpha]
11/13
08:25 am
cadl
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Medium
Report
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
11/4
09:00 am
cadl
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Low
Report
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
11/3
08:05 am
cadl
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
Medium
Report
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
10/27
05:02 pm
cadl
Candel Therapeutics (NASDAQ:CADL) is now covered by analysts at Stephens. They set an "overweight" rating on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) is now covered by analysts at Stephens. They set an "overweight" rating on the stock.
10/21
11:00 am
cadl
Candel Therapeutics (NASDAQ:CADL) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $16.00 price target on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $16.00 price target on the stock.
10/16
08:05 am
cadl
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Medium
Report
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
10/14
08:58 am
cadl
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine [Yahoo! Finance]
Low
Report
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine [Yahoo! Finance]
10/14
08:58 am
cadl
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. [Yahoo! Finance]
Medium
Report
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. [Yahoo! Finance]
10/14
08:42 am
cadl
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer [Yahoo! Finance]
Medium
Report
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer [Yahoo! Finance]
10/14
08:10 am
cadl
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Medium
Report
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
10/14
08:05 am
cadl
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Medium
Report
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
10/13
10:23 am
cadl
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now [Seeking Alpha]
Low
Report
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now [Seeking Alpha]
10/3
09:05 am
cadl
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
Low
Report
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
9/29
12:28 pm
cadl
Candel Therapeutics (NASDAQ:CADL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
9/29
09:23 am
cadl
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 [Yahoo! Finance]
Low
Report
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 [Yahoo! Finance]
9/29
08:05 am
cadl
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Medium
Report
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
9/20
01:09 am
cadl
Candel Therapeutics (NASDAQ:CADL) was upgraded by analysts at
Wall Stree
Medium
Report
Candel Therapeutics (NASDAQ:CADL) was upgraded by analysts at
Wall Stree
9/17
08:05 am
cadl
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Low
Report
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
9/7
10:55 am
cadl
Candel Therapeutics: Potentially The Next Exciting Oncology Story [Seeking Alpha]
Low
Report
Candel Therapeutics: Potentially The Next Exciting Oncology Story [Seeking Alpha]
9/6
12:32 am
cadl
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str
Low
Report
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str